- Zydus Lifesciences teams up with Viwit Pharmaceuticals to market MRI contrast agents in the US.
- The US market for gadobutrol injection is valued at approximately $120 million, while gadoterate meglumine injection is estimated to have a market opportunity of $117 million.
Zydus Lifesciences Ltd., a global healthcare company, announced that its subsidiary, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals. The agreement covers the US market distribution of two generic MRI contrast agents: gadobutrol (generic GADAVIST™) and gadoterate meglumine (generic DOTAREM®).
Under the terms of the agreement, Viwit Pharmaceuticals will handle the Abbreviated New Drug Application (ANDA) submission, manufacturing, and supply of the products, pending regulatory approval. Zydus Lifesciences will focus on marketing, distributing, and selling the products exclusively in the US market. This marks Zydus’ entry into the MRI contrast agent space with these injectable products.
Both gadobutrol and gadoterate meglumine are gadolinium-based contrast agents used in Magnetic Resonance Imaging (MRI) scans. According to IQVIA MAT data from July 2024, the market opportunity for gadobutrol injection in the US is valued at $120 million, while gadoterate meglumine injection is estimated at $117 million.
 Overview of outsourcing trends 
